Neo Comprehensive - Myeloid Disorders

Next Generation Sequencing (NGS)

The Neo Comprehensive - Myeloid Disorders assay analyzes 184 genes to detect DNA and RNA alterations through NGS for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance of myeloid neoplasms. Test reports include a summary interpretation of all results together.

DNA sequencing SNVs/Indels (127 genes):
ABL1, ANKRD26, APC, ARAF, ASXL1, ATM, ATRX, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CHEK2, CSF3R, CTC1, CUX1, CXCR4, DDX41, DKC1, DNMT3A, ELANE, EPCAM, ERCC4, ETNK1, ETV6, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FLT3, G6PC3, GATA1, GATA2, GFI1, GNAS, GNB1, HAX1, HRAS, IDH1, IDH2, IKZF1, IKZF3, ITPKB, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MAP2K1, MET, MLH1, MPL, MSH2, MSH6, MYD88, NF1, NHP2, NOP10, NOTCH1, NPM1, NRAS, PALB2, PDGFRA, PHF6, PIGA, PML, PMS2, PRPF8, PPM1D, PTEN, PTPN11, RAD21, RAD51C, RB1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS26, RPS7, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SLX4, SMC1A, SMC3, SRP72, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TERC, TERT, TET2, TINF2, TP53, U2AF1, VHL, WAS, WRAP53, WT1, ZRSR2

Copy Number Variants (CNV) (17 genes):
ABL1, ASXL1, ATG2B, BRAF, CBFB, CDKN1B, CDKN2A, DNMT1, ETV6, EZH2, GSKIP, JAK2, KMT2A, KRAS, MYC, RAD21, TP53

RNA sequencing Fusions (40 genes):
ABL1, AFDN, AFF1, ALK, BCL11B, CBFB, CEP43, CPSF6, CREBBP, DEK, ELL, EP300, ETV6, FGFR1, FLT3, GLIS2, JAK2, KMT2A, MECOM, MLLT1, MLLT3, MRTFA, MYB, MYH11, NTRK3, NUP214, NUP98, PCM1, PDGFRA, PDGFRB, PICALM, PML, PRDM16, RARA, RBM15, RPN1, RUNX1, RUNX1T1, TCF3, ZNF384

Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the Neo Comprehensive Myeloid Disorders. It is reported separately from the Neo Comprehensive profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.

Turnaround time

14 Days

Level of Service

Global

New York Approved: Yes

Clinical Significance

The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.

Specimen Requirements

Bone Marrow Aspirate: 2-3 mL in EDTA tube. Sodium heparin is acceptable.
Peripheral Blood: 3-5 mL in EDTA tube. Sodium heparin is acceptable.
H&E slide: Required, plus paraffin block.
Cut Slides: H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.
Note on FFPE: Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Do not use: Mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
Note on fresh samples: NeoGenomics should receive within 7 days from collection for acceptable cell viability.
Note: Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - TNA if specimen hold service is desired.

CPT Code(s)*

81455

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Biomarkers

DNA Sequencing

SNVs + Indels
KDM6A	MAP2K1	MPL	PPM1D	NF1	RAD21
RB1	SETD2	SMC1A	SMC3	STAT3	STAT5B
VHL	SUZ12	CBLB	CBLC	ABL1	CDKN2A
ETNK1	FANCB	FANCM	FLT3	GNB1	IKZF1
JAK2	JAK3	IKZF3	ITPKB	ANKRD26	PDGFRA
SH2B3	TP53	ASXL1	BCOR	BRAF	CEBPA
CSF3R	DNMT3A	ETV6	CALR	EZH2	IDH1
KIT	HRAS	KRAS	NPM1	NRAS	PHF6
PTPN11	PRPF8	SETBP1	SF3B1	SRSF2	STAG2
U2AF1	WT1	ZRSR2	BRCA2	BRIP1	TET2
CTC1	DDX41	DKC1	ELANE	SAMD9L	RTEL1
SBDS	SAMD9	IDH2	ERCC4	G6PC3	GFI1
HAX1	KMT2A	NHP2	NOP10	CUX1	PALB2
RAD51C	RPL11	RPL35A	RPL5	RPS10	RPS17
RPS26	RPS7	SLX4	SRP72	TERC	PIGA
TERT	TINF2	WRAP53	PML	WAS	ATM
RUNX1	BRCA1	CHEK2	FANCA	FANCC	FANCD2
FANCE	FANCF	FANCI	FANCL	FANCG	MET
MLH1	MSH2	MSH6	PMS2	PTEN	APC
CXCR4	MYD88	NOTCH1	EPCAM	FBXW7	ATRX
ARAF	BCORL1	BLM	CBL	GATA1	GATA2
GNAS

CNVs
ABL1	ASXL1	CDKN1B	DNMT1	CDKN2A	ETV6
EZH2	KMT2A	MYC	TP53	RAD21	ATG2B
GSKIP	JAK2	KRAS	BRAF

RNA Sequencing

Fusions
PCM1	PML	RARA	RUNX1T1	ALK	MYB
BCL11B	CBFB	CEP43	CPSF6	MYH11	DEK
ABL1	EP300	ETV6	FGFR1	FLT3	JAK2
KMT2A	AFDN	AFF1	NTRK3	NUP98	PDGFRA
PDGFRB	MECOM	MRTFA	RUNX1	TCF3	ZNF384
PICALM	PRDM16	RBM15	RPN1	CREBBP	ELL
GLIS2	MLLT1	MLLT3	NUP214

Fluorescence In Situ Hybridization (FISH)

CNVs
CBFB

Last Updated: January 16, 2026

Get in touch

Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.